临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
XL228
中文名称: N4-(5-环丙基-1H-吡唑-3-基)-N2-[[3-异丙基-5-异恶唑基]甲基]-6-(4-甲基-1-哌嗪基)-2,4-嘧啶二胺
CAS号:898280-07-4
分子式: C22H31N9O 分子量: 437.54
产品形式: Free Base
研发状态: Terminated
研发用途: Cancer; Lymphoma
研究机构: Exelixis
研发日期: Sep-07
研发阶段: Phase 1
XL228 is a protein kinase inhibitor with IC50 of 5 nM, 1.4 nM, 3.1 nM, 1.6 nM, 6.1 nM and 2 nM for wild-type ABL kinase, ABL T315I, Aurora A, IGF-1R, SRC and LYN, respectively.
Aceclofenac
中文名称:醋氯芬酸
CAS号:89796-99-6
分子式: C16H13Cl2NO4 分子量: 354.18
产品形式: free base
研发状态: Completed
研发用途: Drug Interaction Potentiation
研究机构: Il-Yang Pharm. Co. Ltd.
研发日期: November 10 2022
研发阶段: Phase 1
Aceclofenac (Preservex, Airtal) is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory and analgesic properties.
Tazobactam
中文名称:三唑巴坦
CAS号:89786-04-9
分子式: C10H12N4O5S 分子量: 300.29
产品形式: free base
研发状态: Not yet recruiting
研发用途: Cardiogenic Shock; Post-cardiac Surgery; Cardiac Arrest; Extracorporeal Membrane Oxygenation Complication; Infections
研究机构: University Hospital Grenoble
研发日期: September 1 2024
研发阶段: Not Applicable
Tazobactam (Tazobactam acid, Tazobactamum) is a β-lactamases Inhibitor with antibacterial activity. It also inhibits the class D oxacillinase OXA-2. It is used in combination with piperacillin and other β-lactam antibiotics to broaden their spectrum and enhance their effect.
Toremifene Citrate (NK 622)
中文名称:枸橼酸托瑞米芬
CAS号:89778-27-8
分子式: C32H36ClNO8 分子量: 598.08
产品形式: Citrate
研发状态: Withdrawn
研发用途: Risk of Bone Fracture Occurrences
研究机构: GTx; Ipsen
研发日期: Mar-11
研发阶段: Phase 3
Toremifene Citrate (NK 622, NSC 613680) is an oral selective estrogen receptor modulator (SERM), used in the treatment of advanced breast cancer.
APD597
中文名称:4-[[6-[(6-甲基磺酰基-2-甲基吡啶-3-基)氨基]-5-甲氧基嘧啶-4-基]氧基]哌啶-1-羧酸异丙酯
CAS号:897732-93-3
分子式: C21H29N5O6S 分子量: 479.55
产品形式: Free Base
研发状态: Completed
研发用途: Diabetes Mellitus Type 2
研究机构: Johnson & Johnson Pharmaceutical Research & Development L.L.C.
研发日期: Nov-08
研发阶段: Phase 1
APD-597 (JNJ-38431055) is a potent and selective G protein-coupled receptor 119 (GPR119) agonist with EC50 of 46 nM for hGPR119 and an inhibitor of Cytochrome P450 2C9 (CYP2C9) with IC50 of 5.8 μM. APD-597 (JNJ-38431055) is developed for treating Type 2 diabetes (T2D).
Tirbanibulin
中文名称:5-[4-[2-(4-吗啉基)乙氧基]苯基]-N-(苯基甲基)-2-吡啶乙酰胺
CAS号:897016-82-9
分子式: C26H29N3O3 分子量: 431.53
产品形式: free base
研发状态: Completed
研发用途: Actinic Keratosis
研究机构: Medical University of Graz
研发日期: May 11 2023
研发阶段: Phase 4
Tirbanibulin(KX2-391,KX 01), the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
